Ind-Swift Laboratories Limited Q1 FY27 results deck summary

Results deck of 17 Aug 2026, summarised by AI from the filing.

Q1 FY27 Total Revenue ₹193.71 cr, Operating EBITDA ₹33.32 cr, PAT ₹24.68 cr; FY27 revenue growth guided more than 50%.

Key takeaways

1. FY27 guidance Management expects FY27 revenue growth of more than 50% and medium-term revenue CAGR of 20-25% with EBITDA margin expansion of 600-800 bps.
2. CDMO commercialization Viatris, Manx and Arrotex CDMO partnerships/Own-Brands commercialized, expected to contribute ₹200-220 cr incremental revenue in FY27.
3. Growth driver Domestic business expansion supported by high-margin Ethical (76% GM), Own-Brand (51% GM) and CMO (42% GM) segments.
4. Key risk Samba facility EU-GMP and PIC/S upgrade is underway and progressing as planned, with execution risk if delayed.

Original filing on BSE

Ind-Swift Laboratories Limited Q1 FY27 results

As filed: Revenue ₹191 cr (+25% year on year), EBITDA ₹33.4 cr (+300% year on year), PAT ₹24.7 cr (+174% year on year), EBITDA margin 17.5% (+1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹170 cr (+23% year on year), EBITDA ₹20.6 cr, PAT ₹15.1 cr (+22% year on year), EBITDA margin 12.1% (+1,000 bps). Score 48 of 100, In line with trend. Revenue and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate -26%. Profit fell 23% from last quarter. Share price after the results: +49.0% in 28 days (Nifty 500: +0.6%).
• Q3 FY26: Revenue ₹151 cr (+300% year on year), EBITDA ₹4.2 cr, PAT ₹9.5 cr, EBITDA margin 2.8%. Score 75 of 100, Above trend. Revenue growth was well above the company's own trend. Other income 168% of PBT. Share price after the results: +21.0% in 30 days (Nifty 500: −1.1%).
• Q2 FY26: Revenue ₹153 cr (+300% year on year), EBITDA ₹1.0 cr, PAT ₹8.0 cr, EBITDA margin 0.7% (+1,000 bps). Score 79 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 180% of PBT. Profit fell 11% from last quarter. Share price after the results: −5.6% in 28 days (Nifty 500: −0.5%).
• Q1 FY26: Revenue ₹153 cr (+300% year on year), EBITDA ₹3.0 cr, PAT ₹9.0 cr (+300% year on year), EBITDA margin 2.0% (+1,000 bps). Score 85 of 100, Above trend. Revenue and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 150% of PBT. Profit fell 96% from last quarter. Share price after the results: +6.2% in 30 days (Nifty 500: +1.9%).
• Q4 FY25: Revenue ₹138 cr (−65% year on year), EBITDA −₹10.0 cr, PAT ₹222 cr, EBITDA margin -7.3% (+217 bps). Score 39 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin rose 217 bps year on year. Tax rate 3%.
• Q3 FY25: Revenue ₹9.0 cr, EBITDA −₹15.0 cr, PAT ₹0.0 cr, EBITDA margin -166.7%. Not scored. Too small to score: quarter revenue ₹9.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.
• Q2 FY25: Revenue ₹12.0 cr, EBITDA −₹12.0 cr, PAT ₹0.0 cr, EBITDA margin -100.0%. Not scored. Too small to score: quarter revenue ₹12.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Past price moves after results do not indicate future moves. Not a recommendation.

Ind-Swift Laboratories Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (17 Aug 2026), Results deck (17 Aug 2026)
• Q3 FY26: Results deck (4 Feb 2026)
• Q2 FY26: Results deck (14 Jan 2026)